News headlines about Bio-Rad Laboratories (NYSE:BIO) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.9248435895449 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

Bio-Rad Laboratories (NYSE:BIO) opened at 222.22 on Friday. Bio-Rad Laboratories has a 12 month low of $154.89 and a 12 month high of $242.79. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 439.17 and a beta of 0.93. The stock’s 50 day moving average is $220.74 and its 200-day moving average is $217.89.

A number of research firms have weighed in on BIO. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price objective for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus target price of $240.80.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories (BIO) Getting Somewhat Positive News Coverage, Study Shows” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/01/bio-rad-laboratories-bio-getting-somewhat-positive-news-coverage-study-shows.html.

In other news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares in the company, valued at approximately $444,774.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 28.29% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.